secwatch.observer — SEC 8-K summary
======================================

Issuer:     VERTEX PHARMACEUTICALS INC / MA (VRTX)
CIK:        0000875320
Form:       8-K
Filed at:   2022-05-05T23:59:59+00:00
Accession:  0000875320-22-000011
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Vertex Q1 product revenue $2.10B (+22% YoY); reiterates FY 2022 guidance $8.4-8.6B
--------------------------------------------------------------------------------

- Product revenues $2.10B (+22% YoY); TRIKAFTA $1.76B (+48% YoY).
- GAAP diluted EPS $2.96; Non-GAAP diluted EPS $3.52 (up 18% YoY).
- Reaffirmed FY 2022 product revenue guidance $8.4-8.6B.
- Pipeline spans 6 disease areas; positive Phase 2 proof-of-concept studies; more therapies entering clinic H2 2022.
- Changed non-GAAP methodology; no longer exclude certain R&D milestone payments; recast prior periods.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/875320/000087532022000011/0000875320-22-000011-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/875320/000087532022000011/vrtx-20220505.htm
  HTML page:      https://secwatch.observer/filing/0000875320-22-000011

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer